$SCYX
SCYNEXIS INC

2023 Q2 Form 10-Q Financial Statement

#000095017023020486 Filed on May 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $131.5M $1.100M $687.0K
YoY Change 9836.05% 60.12% -94.3%
Cost Of Revenue $426.0K $137.0K $99.00K
YoY Change 195.83% 38.38%
Gross Profit $131.0M $993.0K $588.0K
YoY Change 11013.49% 68.88%
Gross Profit Margin 99.68% 90.27% 85.59%
Selling, General & Admin $7.474M $4.840M $14.59M
YoY Change -52.65% -66.83% 117.91%
% of Gross Profit 5.7% 487.41% 2481.46%
Research & Development $7.040M $6.835M $5.735M
YoY Change -1.28% 19.18% -17.46%
% of Gross Profit 5.37% 688.32% 975.34%
Depreciation & Amortization $153.0K $151.0K $155.0K
YoY Change 4.79% -2.58% 474.07%
% of Gross Profit 0.12% 15.21% 26.36%
Operating Expenses $14.94M $11.81M $20.33M
YoY Change -35.22% -41.89% 48.97%
Operating Profit $116.5M -$10.68M -$19.74M
YoY Change -635.99% -45.88% 1138.27%
Interest Expense $1.249M $1.447M $9.574M
YoY Change 1.46% -84.89% 4373.83%
% of Operating Profit 1.07%
Other Income/Expense, Net $5.746M -$23.19M $9.587M
YoY Change -31.54% -341.93% -583.7%
Pretax Income $122.3M -$33.88M -$10.15M
YoY Change -1016.15% 233.72% 183.86%
Income Tax $0.00 $0.00 -$4.700M
% Of Pretax Income 0.0%
Net Earnings $122.3M -$33.88M -$5.451M
YoY Change -1016.15% 521.46% 16.57%
Net Earnings / Revenue 93.01% -3079.64% -793.45%
Basic Earnings Per Share $2.56 -$0.71 -$0.17
Diluted Earnings Per Share $2.46 -$0.71 -$0.18
COMMON SHARES
Basic Shares Outstanding 36.52M 33.32M 32.05M
Diluted Shares Outstanding 49.92M 47.76M 33.19M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $85.54M $54.82M $95.21M
YoY Change -27.93% -42.42% 3.49%
Cash & Equivalents $57.91M $26.91M $95.20M
Short-Term Investments $27.64M $27.91M
Other Short-Term Assets $1.110M $291.0K $4.000K
YoY Change 27650.0% 7175.0% -98.92%
Inventory $10.29M $1.105M $1.149M
Prepaid Expenses
Receivables $2.345M $2.060M $1.628M
Other Receivables $25.00M $0.00 $0.00
Total Short-Term Assets $145.5M $59.77M $101.9M
YoY Change 15.8% -41.35% 6.82%
LONG-TERM ASSETS
Property, Plant & Equipment $2.484M $2.540M $2.810M
YoY Change -7.9% -9.61% -12.19%
Goodwill
YoY Change
Intangibles $206.0K $309.0K
YoY Change -76.21%
Long-Term Investments $6.336M
YoY Change
Other Assets $64.00K $7.444M $5.885M
YoY Change -98.95% 26.49% 435.0%
Total Long-Term Assets $9.326M $10.53M $9.656M
YoY Change -6.14% 9.04% 105.45%
TOTAL ASSETS
Total Short-Term Assets $145.5M $59.77M $101.9M
Total Long-Term Assets $9.326M $10.53M $9.656M
Total Assets $154.9M $70.30M $111.6M
YoY Change 14.19% -36.99% 11.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.416M $5.925M $8.130M
YoY Change -65.7% -27.12% 25.08%
Accrued Expenses $7.190M $4.775M $4.523M
YoY Change 33.25% 5.57% 111.95%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $34.65M $0.00
YoY Change
Total Short-Term Liabilities $16.16M $45.64M $12.94M
YoY Change 0.91% 252.63% -48.02%
LONG-TERM LIABILITIES
Long-Term Debt $11.63M $11.41M $44.53M
YoY Change -74.01% -74.38% 265.0%
Other Long-Term Liabilities $33.99M $43.16M $4.102M
YoY Change 571.61% 952.15% -88.91%
Total Long-Term Liabilities $45.62M $54.57M $4.102M
YoY Change 801.4% 1230.23% -91.66%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.16M $45.64M $12.94M
Total Long-Term Liabilities $45.62M $54.57M $4.102M
Total Liabilities $61.78M $100.2M $72.64M
YoY Change -31.46% 37.96% -2.04%
SHAREHOLDERS EQUITY
Retained Earnings -$333.9M -$456.2M -$364.9M
YoY Change -11.74% 25.02% 10.14%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $93.08M -$29.91M $38.93M
YoY Change
Total Liabilities & Shareholders Equity $154.9M $70.30M $111.6M
YoY Change 14.19% -36.99% 11.48%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income $122.3M -$33.88M -$5.451M
YoY Change -1016.15% 521.46% 16.57%
Depreciation, Depletion And Amortization $153.0K $151.0K $155.0K
YoY Change 4.79% -2.58% 474.07%
Cash From Operating Activities $74.40M -$18.92M -$15.99M
YoY Change -500.4% 18.36% 2003.68%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$9.000K
YoY Change -100.0% -95.5%
Acquisitions
YoY Change
Other Investing Activities -$6.384M
YoY Change
Cash From Investing Activities -$6.384M $0.00 -$9.000K
YoY Change -100.0% -95.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.164M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -36.64M 22.00K 6.723M
YoY Change -187.11% -99.67% -9569.01%
NET CHANGE
Cash From Operating Activities 74.40M -18.92M -15.99M
Cash From Investing Activities -6.384M 0.000 -9.000K
Cash From Financing Activities -36.64M 22.00K 6.723M
Net Change In Cash 31.37M -18.90M 6.714M
YoY Change 33.61% -381.52% -2577.49%
FREE CASH FLOW
Cash From Operating Activities $74.40M -$18.92M -$15.99M
Capital Expenditures $0.00 -$9.000K
Free Cash Flow -$18.92M -$15.98M
YoY Change 18.42% 2753.39%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001178253
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2023Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-36365
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
SCYNEXIS, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
56-2181648
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1 Evertrust Plaza
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
13th Floor
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Jersey City
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07302-6548
CY2023Q1 dei City Area Code
CityAreaCode
201
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
884-5485
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
SCYX
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36517442
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26913000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45814000
CY2023Q1 us-gaap Short Term Investments
ShortTermInvestments
27908000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
27689000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1726000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2503000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2060000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2101000
CY2023Q1 us-gaap Inventory Net
InventoryNet
1105000
CY2022Q4 us-gaap Inventory Net
InventoryNet
899000
CY2023Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
55000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
55000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
59767000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
79061000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7444000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5511000
CY2023Q1 us-gaap Deferred Costs
DeferredCosts
73000
CY2022Q4 us-gaap Deferred Costs
DeferredCosts
73000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
163000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
163000
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
309000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
408000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2540000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2594000
CY2023Q1 us-gaap Assets
Assets
70296000
CY2022Q4 us-gaap Assets
Assets
87810000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5925000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5937000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4775000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5628000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
0
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5771000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
296000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
282000
CY2023Q1 us-gaap Loans Payable Current
LoansPayableCurrent
34648000
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
0
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
45644000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17618000
CY2023Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
40317000
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
18644000
CY2023Q1 scyx Convertible Debt And Derivative Liability
ConvertibleDebtAndDerivativeLiability
11407000
CY2022Q4 scyx Convertible Debt And Derivative Liability
ConvertibleDebtAndDerivativeLiability
11001000
CY2023Q1 us-gaap Long Term Loans Payable
LongTermLoansPayable
0
CY2022Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
34393000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2842000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2921000
CY2023Q1 us-gaap Liabilities
Liabilities
100210000
CY2022Q4 us-gaap Liabilities
Liabilities
84577000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0
CY2022Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33327627
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33327627
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32682342
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32682342
CY2023Q1 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
36000
CY2022Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
36000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
426214000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
425485000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-456164000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-422288000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-29914000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3233000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
70296000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
87810000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1130000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
687000
CY2023Q1 scyx Cost Of Product Revenues
CostOfProductRevenues
137000
CY2022Q1 scyx Cost Of Product Revenues
CostOfProductRevenues
99000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6835000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5735000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4840000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14591000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
11812000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
20425000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10682000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-19738000
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
255000
CY2022Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
390000
CY2023Q1 us-gaap Interest Income Other
InterestIncomeOther
587000
CY2022Q1 us-gaap Interest Income Other
InterestIncomeOther
13000
CY2023Q1 us-gaap Interest Expense
InterestExpense
1447000
CY2022Q1 us-gaap Interest Expense
InterestExpense
1059000
CY2023Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
0
CY2022Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
13000
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
21673000
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-10030000
CY2023Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-406000
CY2022Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
980000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-23194000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9587000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33876000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10151000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4700000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-33876000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5451000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47757246
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32051228
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47757246
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33189428
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-33876000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-5451000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
151000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
155000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
707000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
922000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
219000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
255000
CY2022Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
390000
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
21673000
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-10030000
CY2023Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-406000
CY2022Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
980000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
54000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
52000
CY2023Q1 scyx Write Off Of Deferred Asset For Commitment Fees
WriteOffOfDeferredAssetForCommitmentFees
514000
CY2022Q1 scyx Write Off Of Deferred Asset For Commitment Fees
WriteOffOfDeferredAssetForCommitmentFees
0
CY2023Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
1887000
CY2022Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
1429000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-6701000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
383000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18923000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15988000
CY2023Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0
CY2022Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
9000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2164000
CY2023Q1 scyx Payments Of Offering Costs And Underwriting Discounts And Commissions
PaymentsOfOfferingCostsAndUnderwritingDiscountsAndCommissions
0
CY2022Q1 scyx Payments Of Offering Costs And Underwriting Discounts And Commissions
PaymentsOfOfferingCostsAndUnderwritingDiscountsAndCommissions
451000
CY2023Q1 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
0
CY2022Q1 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
5000000
CY2023Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
4000
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
10000
CY2023Q1 scyx Payments For Proceeds From Repurchase Of Shares To Satisfy Tax Withholdings
PaymentsForProceedsFromRepurchaseOfSharesToSatisfyTaxWithholdings
-18000
CY2022Q1 scyx Payments For Proceeds From Repurchase Of Shares To Satisfy Tax Withholdings
PaymentsForProceedsFromRepurchaseOfSharesToSatisfyTaxWithholdings
0
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6723000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-18901000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-9274000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46032000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104702000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27131000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
95428000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
1658000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
1099000
CY2023Q1 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
373000
CY2022Q1 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
12000
CY2023Q1 scyx Deferred Offering Costs Incurred But Not Yet Paid
DeferredOfferingCostsIncurredButNotYetPaid
0
CY2022Q1 scyx Deferred Offering Costs Incurred But Not Yet Paid
DeferredOfferingCostsIncurredButNotYetPaid
26000
CY2023Q1 scyx Deferred Offering Costs Reclassified To Additional Paid In Capital
DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital
0
CY2022Q1 scyx Deferred Offering Costs Reclassified To Additional Paid In Capital
DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital
27000
CY2023Q1 scyx Reclass Of Warrant Liability To Additional Paid In Capital
ReclassOfWarrantLiabilityToAdditionalPaidInCapital
0
CY2022Q1 scyx Reclass Of Warrant Liability To Additional Paid In Capital
ReclassOfWarrantLiabilityToAdditionalPaidInCapital
71000
CY2023Q1 scyx Reclass Of Deferred Asset Issuance Of Loan Payable To Debt Discount
ReclassOfDeferredAssetIssuanceOfLoanPayableToDebtDiscount
0
CY2022Q1 scyx Reclass Of Deferred Asset Issuance Of Loan Payable To Debt Discount
ReclassOfDeferredAssetIssuanceOfLoanPayableToDebtDiscount
206000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-33900000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-62800000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-456200000
CY2023Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
54800000
CY2023Q1 scyx Debt Instrument Minimum Outstanding Term Loan Principal Percentage For Financial Covenant Waived
DebtInstrumentMinimumOutstandingTermLoanPrincipalPercentageForFinancialCovenantWaived
0.50
CY2023Q1 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
0
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-33876000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5451000
CY2023Q1 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
0
CY2022Q1 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
-584000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-33876000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6035000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47757246
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32051228
CY2023Q1 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0
CY2022Q1 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
1138200
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47757246
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33189428
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27332890
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10879564
CY2023Q1 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
27908000
CY2023Q1 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
0
CY2023Q1 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
64000
CY2023Q1 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
27844000
CY2022Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
27689000
CY2022Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
0
CY2022Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
160000
CY2022Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
27529000
CY2023Q1 us-gaap Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount
27900000
CY2023Q1 scyx Prepaid Researchand Development Expenses Current
PrepaidResearchandDevelopmentExpensesCurrent
569000
CY2022Q4 scyx Prepaid Researchand Development Expenses Current
PrepaidResearchandDevelopmentExpensesCurrent
635000
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
328000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
622000
CY2023Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
538000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1184000
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
291000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
62000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1726000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2503000
CY2023Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
7724000
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
5093000
CY2023Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
698000
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
610000
CY2023Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
11000
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
24000
CY2023Q1 scyx Inventory Current And Noncurrent Net
InventoryCurrentAndNoncurrentNet
8433000
CY2022Q4 scyx Inventory Current And Noncurrent Net
InventoryCurrentAndNoncurrentNet
5727000
CY2023Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The Company has the option to renew for two consecutive five-year periods from the end of the first term and the Company is not reasonably certain that the option to renew the Lease will be exercised. Under the Lease, the Company furnished a security deposit in the form of a standby letter of credit in the amount of $0.3 million, which was reduced by fifty-five thousand dollars on the first anniversary of the commencement date. The security deposit will continue to be reduced by fifty-five thousand dollars every two years on the commencement date anniversary for eight years.
CY2018Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2018Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2023Q1 scyx Accrued Researchand Development Expense Current
AccruedResearchandDevelopmentExpenseCurrent
1249000
CY2022Q4 scyx Accrued Researchand Development Expense Current
AccruedResearchandDevelopmentExpenseCurrent
786000
CY2023Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
498000
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1628000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1543000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1313000
CY2023Q1 scyx Accrued Severance
AccruedSeverance
28000
CY2022Q4 scyx Accrued Severance
AccruedSeverance
688000
CY2023Q1 scyx Accrued Rebates Current
AccruedRebatesCurrent
760000
CY2022Q4 scyx Accrued Rebates Current
AccruedRebatesCurrent
595000
CY2023Q1 scyx Accrued Other Rebates
AccruedOtherRebates
697000
CY2022Q4 scyx Accrued Other Rebates
AccruedOtherRebates
618000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4775000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5628000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
35000000
CY2023Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
35000000
CY2023Q1 scyx Debt Instrument Final Fee Due At Maturity
DebtInstrumentFinalFeeDueAtMaturity
1383000
CY2023Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
36383000
CY2023Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1735000
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
34648000
CY2023Q1 scyx Deferred Fees Paid
DeferredFeesPaid
5800000
CY2018Q1 scyx Lease Agreement Area Of Office Space
LeaseAgreementAreaOfOfficeSpace
19275
CY2018Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P11Y
CY2018Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
7300000
CY2018Q1 us-gaap Security Deposit
SecurityDeposit
300000
CY2018Q1 us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
55000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
166000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
166000
CY2023Q1 scyx Variable Lease Cost Credit
VariableLeaseCostCredit
58000
CY2022Q1 scyx Variable Lease Cost Credit
VariableLeaseCostCredit
-3000
CY2023Q1 us-gaap Lease Cost
LeaseCost
224000
CY2022Q1 us-gaap Lease Cost
LeaseCost
163000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
177000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
174000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y4M2D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y7M2D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.15
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.15
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
538000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
730000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
744000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
759000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
774000
CY2023Q1 scyx Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
1256000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4801000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3138000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
296000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2842000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3138000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1663000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33327627
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33327627
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32682342
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32682342
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3233000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-33876000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
707000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
4000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
18000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-29914000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
41258000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5451000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
922000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2135000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
10000
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-18000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
71000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
38927000
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
42993456
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
42489050
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
21700000
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-10000000.0
CY2023Q1 scyx Fair Value Of Liabilities
FairValueOfLiabilities
40300000
CY2022Q4 scyx Fair Value Of Liabilities
FairValueOfLiabilities
18600000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1740308
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.21
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M28D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
225000
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.54
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
33919
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
7.35
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1931389
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.05
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y5M12D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
544000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1202326
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
15.70
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P4Y9M25D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
10000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1931389
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
11.05
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y5M12D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
544000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
700000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
900000
CY2023Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2022Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
707000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
922000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1100000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
700000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1541000
CY2023Q1 scyx Contract With Customer Liability Provision Related To Current Period Revenue
ContractWithCustomerLiabilityProvisionRelatedToCurrentPeriodRevenue
1347000
CY2023Q1 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
0
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1025000
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1863000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1380000
CY2022Q1 scyx Contract With Customer Liability Provision Related To Current Period Revenue
ContractWithCustomerLiabilityProvisionRelatedToCurrentPeriodRevenue
1374000
CY2022Q1 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
0
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1162000
CY2022Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1592000

Files In Submission

Name View Source Status
0000950170-23-020486-index-headers.html Edgar Link pending
0000950170-23-020486-index.html Edgar Link pending
0000950170-23-020486.txt Edgar Link pending
0000950170-23-020486-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img217347157_0.jpg Edgar Link pending
img217347157_1.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
scyx-20230331.htm Edgar Link pending
scyx-20230331.xsd Edgar Link pending
scyx-ex10_1.htm Edgar Link pending
scyx-ex10_2.htm Edgar Link pending
scyx-ex10_3.htm Edgar Link pending
scyx-ex31_1.htm Edgar Link pending
scyx-ex31_2.htm Edgar Link pending
scyx-ex32_1.htm Edgar Link pending
Show.js Edgar Link pending
scyx-20230331_cal.xml Edgar Link unprocessable
scyx-20230331_lab.xml Edgar Link unprocessable
scyx-20230331_def.xml Edgar Link unprocessable
scyx-20230331_pre.xml Edgar Link unprocessable
scyx-20230331_htm.xml Edgar Link completed